Personal Finance
The Survival Odds For Pancreatic Cancer Just Got Better…. A Lot Better! – Equity Insider
In late 2022, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) Put Out Historically Incredible Numbers in its Latest GOBLET Study, including a Near TRIPLING of Objective Response Rate (ORR), and a Statistically Rare Complete Response (CR)—LEADING TO THE FDA GRANTING FAST TRACK DESIGNATION FOR PELAREOREP. Now ONCY is Going into the 2023 ASCO Annual Meeting with Another…
Read the full article here